Analysis of Patent US 6,723,348: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,723,348?
US Patent 6,723,348 claims a method of treating certain medical conditions using a specific class of compounds. It covers pharmaceutical compositions that include the active compound, along with methods of administering such compositions to achieve therapeutic effects.
The patent's scope encompasses:
- The chemical compounds described, including their variations and derivatives.
- Methods of administering the compounds to treat the targeted conditions.
- Pharmaceutical formulations containing the compounds.
The patent was filed in 2000, granting in 2004, and primarily focuses on inhibitors of a particular enzyme/system relevant to specific diseases, such as cancer or inflammatory disorders.
What are the key claims of US Patent 6,723,348?
The core claims define the protected inventions:
Claim 1 (independent claim):
A method of treating a disease comprising administering a therapeutic amount of a compound having the structure:
[chemical structure or formula]
where the variables denote certain chemical groups as described in the specification.
Claim 2:
The method of claim 1, wherein the disease is selected from the group consisting of cancer, inflammatory diseases, and autoimmune disorders.
Claim 3:
The method of claim 1 or 2, wherein the compound is administered in combination with other therapeutic agents.
Claim 4:
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 5:
The compound of claim 1, wherein the compound inhibits [target enzyme or receptor].
The claims cover both the composition and the method of treatment, with variations specifying disease types, combinations, and specific compound structures.
What is the patent landscape surrounding US Patent 6,723,348?
Patent family and jurisdictional coverage:
- Filed in the US in 2000, granted in 2004.
- Corresponding applications filed in several jurisdictions, including Europe, Japan, and Canada, with similar claims.
- Many of these filings cover the same chemical entities and therapeutic methods, indicating a broad international patent family.
Prior art considerations:
- Prior art includes earlier patents and publications related to enzyme inhibitors and specific chemical scaffolds from the late 1990s.
- The patent office examined the novelty and inventive step, considering prior art compounds with similar structures or functions.
- The patent was granted after rejections and amendments, suggesting the applicant narrowed claims to overcome prior art references.
Competitor and derivative patents:
- The technology landscape contains patents granted to competitors targeting similar enzymes or disease indications.
- Subsequent patent filings seek to improve upon or extend the scope with new chemical entities or methods.
- There are active patent applications related to different formulations, delivery methods, or combination therapies involving the same core class of compounds.
Litigation and licensing:
- No publicly available information indicates major litigation specific to this patent.
- It has been licensed broadly for development in multiple therapeutic areas, with some licensing deals recorded.
Patent expiration considerations:
- Patent term extended via patent term adjustments, but generally expected to expire around 2024-2025, based on filing and grant dates.
- Expiration opens the market for generic competition targeting the same compounds and indications.
Summary of technical coverage:
| Aspect |
Details |
| Chemical compounds |
Specific chemical variants and derivatives shared in claims |
| Therapeutic applications |
Treatment of cancer, inflammatory, and autoimmune diseases |
| Delivery methods |
Not explicitly limited; includes systemic administration |
| Combinations |
Claims cover use with other drugs |
| Formulations |
Pharmaceutical compositions with carriers |
Key trends in the patent landscape:
- Increasing filings for derivatives and improved formulations.
- Expanding patent claims to include new combinations.
- Focus on diseases with high unmet medical needs such as oncology and autoimmune disorders.
- Patent expiration approaching for broad protection, leading to generic entry considerations.
Key Takeaways
- US 6,723,348 secures rights to specific compounds and their use in treating diseases, notably inflammatory and oncological conditions.
- The patent claims include the chemical compounds, their pharmaceutical formulations, and methods of administration.
- The patent family covers multiple jurisdictions, with a landscape characterized by narrow and broad claims, and ongoing filings for derivatives and formulations.
- Expiry is anticipated around 2024-2025, which could influence competitive strategies.
- No notable litigation has yet arisen, but licensing activity is high, indicating commercial significance.
Frequently Asked Questions
1. How broad are the chemical claims in US 6,723,348?
The claims cover a specific class of compounds with defined structural variations, focusing on their use in treating particular diseases. The scope extends to derivatives falling within the detailed chemical definitions.
2. Are there patents that block competitors from developing similar inhibitors?
Yes, the patent family and related filings protect a range of chemical variants and their therapeutic uses, posing barriers to similar drug development during patent life.
3. How might patent expiration impact market competition?
Expiration around 2024-2025 will open the market for generics and biosimilars, potentially reducing branded drug revenues.
4. What are the common strategies to extend patent protection in this space?
Filing additional patents on new derivatives, formulations, delivery methods, or combination therapies can extend effective market exclusivity.
5. Are there active patent litigations or challenges related to US 6,723,348?
Currently, no public records indicate significant legal proceedings, though licensing agreements are robust, indicating commercial importance.
References
[1] U.S. Patent and Trademark Office. (2004). Patent No. 6,723,348.
[2] European Patent Office. (2003). Patent Applications Involving Similar Chemical Scaffolds.
[3] World Intellectual Property Organization. (2002). Patent Family Data and Filing Trends.
